Stable gastric pentadecapeptide
BPC 157 is an anti-
ulcer peptidergic agent, proven in clinical trials to be both safe in
inflammatory bowel disease (PL-10,
PLD-116, PL 14736) and wound healing, stable in human gastric juice, with no toxicity being reported. Recently, we claim that
BPC 157 may be used as an
antidote against
NSAIDs. We focused on
BPC 157 beneficial effects on stomach, duodenum, intestine, liver and
brain injuries,
adjuvant arthritis,
pain, hyper/
hypothermia, obstructive
thrombus formation and thrombolysis, blood vessel function, counteraction of prolonged
bleeding and
thrombocytopenia after application of various
anticoagulants and
antiplatelet agents and wound healing improvement. The arguments for
BPC 157 antidote activity (i.e., the role of
BPC 157 in cytoprotection, being a novel mediator of Robert's cytoprotection and
BPC 157 beneficial effects on
NSAIDs mediated lesions in the gastrointestinal tract, liver and brain and finally, counteraction of
aspirin-induced prolonged
bleeding and
thrombocytopenia) obviously have a counteracting effect on several established side-effects of
NSAIDs use. The mentioned variety of the beneficial effects portrayed by
BPC 157 may well be a foundation for establishing
BPC 157 as a
NSAIDs antidote since no other single agent has portrayed a similar array of effects. Unlike
NSAIDs, a very high safety (no reported toxicity (LD1 could be not achieved)) profile is reported for
BPC 157. Also, unlike the different dosage levels of
aspirin, as a
NSAIDs prototype, which differ by
a factor of about ten, all these beneficial and counteracting effects of
BPC 157 were obtained using the equipotent dosage (μg, ng/kg) in parenteral or peroral regimens.